Understanding Ozempic Gastroparesis: What the Research Shows

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Legal Awareness

If you are experiencing persistent nausea, vomiting, or abdominal pain after taking Ozempic, you may be concerned about gastroparesis. This condition, characterized by delayed stomach emptying, has been increasingly reported in people using GLP-1 receptor agonists. Building on decades of medical education, this page provides a clear overview of the symptoms and current research on Ozempic-related gastroparesis.

Understanding Ozempic and Its Link to Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its pharmacological action includes slowing gastric emptying, which is a known mechanism that can contribute to gastrointestinal adverse effects. Gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, presents clinically with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy or breath tests to confirm delayed emptying. The clinical presentation of gastroparesis overlaps significantly with the gastrointestinal adverse reactions reported in Ozempic clinical trials. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients included nausea (placebo 6.1%, Ozempic 0.5 mg 15.8%, Ozempic 1 mg 20.3%), vomiting (placebo 2.3%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 9.2%), diarrhea (placebo 1.9%, Ozempic 0.5 mg 8.5%, Ozempic 1 mg 8.8%), abdominal pain (placebo 4.6%, Ozempic 0.5 mg 7.3%, Ozempic 1 mg 5.7%), and constipation (placebo 1.5%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 3.1%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Mechanistic Pathway and Warning Gaps

The mechanistic pathway linking Ozempic to gastroparesis involves its action as a GLP-1 receptor agonist, which slows gastric emptying. This effect is dose-dependent and can lead to prolonged gastric retention, potentially causing or exacerbating gastroparesis in susceptible individuals. While the drug label does not explicitly list gastroparesis as a warning, the high rates of nausea, vomiting, and abdominal pain—symptoms that overlap with gastroparesis—raise questions about the adequacy of warnings. The label includes a warning for hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but does not specifically address the risk of gastroparesis. This gap in warning may be relevant for patients who develop severe or persistent gastrointestinal symptoms that meet diagnostic criteria for gastroparesis.

Statute of Limitations for Ozempic Claims in Ohio

For affected patients in Ohio, attorney-related considerations include the statute of limitations for product liability claims. In Ohio, the statute of limitations for personal injury claims is generally two years from the date of injury or from when the injury was discovered or should have been discovered with reasonable diligence. For claims involving inadequate warnings, the timeline between exposure to Ozempic and documented harm is critical. Patients who experienced gastrointestinal symptoms during dose escalation or after prolonged use should document the onset of symptoms, medical evaluations, and any diagnosis of gastroparesis. The timing of harm relative to the initiation of Ozempic is important because the majority of gastrointestinal adverse reactions occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), suggesting a temporal relationship. However, some patients may develop symptoms later, and the chronic nature of gastroparesis can complicate the determination of when the injury was discovered. Patients considering legal action should consult with an attorney experienced in pharmaceutical litigation to evaluate the specific facts of their case, including the adequacy of warnings provided by the manufacturer. The evidence from clinical trials indicates that gastrointestinal adverse reactions are common and dose-related, but the label does not explicitly warn about gastroparesis. This may form the basis of a claim that the manufacturer failed to adequately warn about a known risk. The statute of limitations in Ohio requires prompt action, as delays could bar recovery. Patients should gather medical records documenting their Ozempic use, symptom onset, and any diagnosis of gastroparesis to establish the timeline between exposure and harm.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Ohio?

In Ohio, the statute of limitations for personal injury claims, including product liability claims related to Ozempic and gastroparesis, is generally two years from the date of injury or from when the injury was discovered or should have been discovered with reasonable diligence. It is crucial to act promptly to preserve your legal rights.

How does Ozempic cause gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying. This mechanism can lead to prolonged gastric retention, potentially causing or exacerbating gastroparesis in susceptible individuals. Clinical trials have shown high rates of gastrointestinal adverse reactions such as nausea, vomiting, and abdominal pain, which overlap with gastroparesis symptoms.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.